The case fatality rate of MH has decreased to less than 5% with dantrolene therapy and advanced intraoperative monitoring techniques. However, the costs involved with continuous temperature monitoring and stocking dantrolene owing to its 3-year shelf-life limit, as well as the relatively high cost of the drug can also be issues that may govern the formulation of public health policies. Further, the paucity of epidemiologic data on MH leads to uncertainty regarding its true incidence, which limits analysis of cost-effectiveness.